Shockwave Medical, Inc. (NASDAQ:SWAV) Receives Average Recommendation of "Hold" from Analysts

Shares of Shockwave Medical, Inc. (NASDAQ:SWAV - Get Free Report) have been given a consensus rating of "Hold" by the eleven analysts that are currently covering the company, Marketbeat Ratings reports. Ten analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $309.11.

A number of brokerages have recently weighed in on SWAV. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $335.00 price objective (up from $270.00) on shares of Shockwave Medical in a research note on Monday, April 8th. Wells Fargo & Company boosted their price objective on shares of Shockwave Medical from $200.00 to $210.00 and gave the stock an "equal weight" rating in a research note on Friday, February 16th. Piper Sandler boosted their price objective on shares of Shockwave Medical from $290.00 to $360.00 and gave the stock an "overweight" rating in a research note on Tuesday, April 2nd. Wolfe Research reiterated a "peer perform" rating on shares of Shockwave Medical in a research note on Friday, April 5th. Finally, SVB Leerink reiterated a "market perform" rating and set a $335.00 target price (down from $361.00) on shares of Shockwave Medical in a research note on Monday, April 8th.

Insider Buying and Selling at Shockwave Medical

In other Shockwave Medical news, CFO Dan Puckett sold 3,406 shares of the business's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $229.76, for a total value of $782,562.56. Following the sale, the chief financial officer now owns 27,732 shares of the company's stock, valued at approximately $6,371,704.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Shockwave Medical news, CFO Dan Puckett sold 3,406 shares of the business's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $229.76, for a total value of $782,562.56. Following the sale, the chief financial officer now owns 27,732 shares of the company's stock, valued at approximately $6,371,704.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Frank T. Watkins sold 2,000 shares of the company's stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $231.76, for a total transaction of $463,520.00. Following the completion of the sale, the director now directly owns 4,532 shares in the company, valued at approximately $1,050,336.32. The disclosure for this sale can be found here. Insiders have sold 89,813 shares of company stock valued at $22,863,919 in the last 90 days. 3.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Shockwave Medical

Several large investors have recently made changes to their positions in the company. YHB Investment Advisors Inc. bought a new stake in shares of Shockwave Medical in the 1st quarter worth about $28,000. Clear Creek Financial Management LLC bought a new stake in Shockwave Medical during the 1st quarter worth about $324,000. MONECO Advisors LLC bought a new stake in Shockwave Medical during the 1st quarter worth about $337,000. WCM Investment Management LLC grew its holdings in Shockwave Medical by 1.4% during the 1st quarter. WCM Investment Management LLC now owns 157,800 shares of the company's stock worth $51,384,000 after acquiring an additional 2,131 shares during the last quarter. Finally, HMS Capital Management LLC bought a new stake in Shockwave Medical during the 1st quarter worth about $384,000. Institutional investors own 95.35% of the company's stock.

Shockwave Medical Stock Up 0.3 %

NASDAQ SWAV traded up $1.01 during trading on Friday, reaching $330.00. The company's stock had a trading volume of 575,689 shares, compared to its average volume of 2,009,896. The company has a current ratio of 11.76, a quick ratio of 10.73 and a debt-to-equity ratio of 1.09. The stock has a market capitalization of $12.34 billion, a PE ratio of 85.27, a PEG ratio of 2.44 and a beta of 0.92. The business has a 50-day moving average price of $294.88 and a 200-day moving average price of $233.41. Shockwave Medical has a 1-year low of $157.00 and a 1-year high of $331.58.

Shockwave Medical (NASDAQ:SWAV - Get Free Report) last posted its earnings results on Thursday, February 15th. The company reported $1.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.92 by $0.24. Shockwave Medical had a net margin of 20.17% and a return on equity of 23.97%. The firm had revenue of $202.98 million during the quarter, compared to analysts' expectations of $199.43 million. During the same period in the previous year, the company earned $3.71 earnings per share. The company's revenue was up 41.0% compared to the same quarter last year. On average, research analysts forecast that Shockwave Medical will post 4.94 earnings per share for the current fiscal year.

About Shockwave Medical

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.